These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 6704303)

  • 1. Effect of the nitroimidazole Ro 03-8799 on the activity of chemotherapeutic agents against a murine tumour in vivo.
    Sheldon PW; Gibson P
    Br J Cancer; 1984 Mar; 49(3):291-300. PubMed ID: 6704303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of melphalan activity against a murine tumour by nitroimidazole compounds.
    Sheldon PW; Batten EL; Adams GE
    Br J Cancer; 1982 Oct; 46(4):525-31. PubMed ID: 7138761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation in vivo of melphalan activity by nitroimidazole compounds.
    Sheldon PW; Batten EL
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):635-7. PubMed ID: 7107388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitization of mouse tumors by misonidazole.
    Randhawa VS; Stewart FA; Denekamp J
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):671-4. PubMed ID: 7107397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Nitroimidazole potentiation of nitrosourea induced cytotoxicity in subcutaneous implants of rat 9L brain tumor cells.
    Wong KH; Wallen CA; Wheeler KT
    J Neurooncol; 1991 Aug; 11(1):17-25. PubMed ID: 1833513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole.
    Stephens TC; Courtenay VD; Mills J; Peacock JH; Rose CM; Spooner D
    Br J Cancer; 1981 Apr; 43(4):451-7. PubMed ID: 7236488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of cyclophosphamide cytotoxicity in vivo: a study with misonidazole and fifteen other 1-substituted 2-nitroimidazoles.
    Chaplin DJ; Sheldon PW; Ahmed I; Adams GE
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1647-51. PubMed ID: 6480452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
    Li LH; DeKoning TF; Wallace TL
    Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts.
    Clutterbuck RD; Millar JL; McElwain TJ
    Am J Clin Oncol; 1982 Feb; 5(1):73-8. PubMed ID: 7081141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of resistance and therapeutic synergism among alkylating agents.
    Schabel FM; Trader MW; Laster WR; Wheeler GP; Witt MH
    Antibiot Chemother (1971); 1978; 23():200-15. PubMed ID: 348078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo.
    Papadopoulou MV; Ji M; Bloomer WD
    Oncol Res; 2003; 13(12):561-6. PubMed ID: 12899246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitrosoureas: a review of experimental antitumor activity.
    Schabel FM
    Cancer Treat Rep; 1976 Jun; 60(6):665-98. PubMed ID: 782694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of alkylating agent cytotoxicity by cisplatin.
    Horsman MR; Hirst DG; Brown DM; Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1669-73. PubMed ID: 6541216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy against B16 melanoma: bleomycin/vinblastine, bleomycin/cis-diamminedichloroplatinum, 5-fluorouracil/BCNU and 5-fluorouracil/methyl-CCNU.
    Mabel JA; Merker PC; Sturgeon ML; Wodinsky I; Geran RI
    Cancer; 1978 Oct; 42(4):1711-9. PubMed ID: 81716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
    Siemann DW
    Br J Cancer; 1990 Sep; 62(3):348-53. PubMed ID: 2206941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.
    Hirst DG; Brown JM; Hazlehurst JL
    Br J Cancer; 1982 Jul; 46(1):109-16. PubMed ID: 7201845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemopotentiation in vivo: no loss of sensitization with fractionation.
    Hill SA; Siemann DW
    Br J Cancer; 1984 Oct; 50(4):509-17. PubMed ID: 6487517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The antitumor properties of honey].
    Gribel' NV; Pashinskiĭ VG
    Vopr Onkol; 1990; 36(6):704-9. PubMed ID: 2378090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.
    Patterson LH; McKeown SR; Ruparelia K; Double JA; Bibby MC; Cole S; Stratford IJ
    Br J Cancer; 2000 Jun; 82(12):1984-90. PubMed ID: 10864207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimum time sequence for the administration of cyclophosphamide and other drugs in vivo.
    Mattern J; Wauss K; Volm M
    Anticancer Res; 1985; 5(2):173-8. PubMed ID: 4039550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.